Patients being dosed and the sites all open bodes well for the trial maintaining a quick pace, as the first Phase 2 study did. Cellceutix is expecting an interim analysis during the upcoming March-June quarter and complete top-line results in the next 6-9 months. If data is consistent with earlier research suggesting a greater therapeutic benefit via a higher dose in patients with more severe psoriasis, it could be a watershed milestone for the company, given that Cellceutix has mentioned being in conversations with big pharma. It’s likely that the addition of Dr. Arthur Bertolino, who held executive positions in dermatology divisions of Pfizer (NYSEFE) and Novartis, as Cellceutix’s President and CMO is instrumental in these discussions.